PDS Biotechnology is listed on NASDAQ.
PDS Biotech was established with the goal of harnessing the power of T cells to address some of the most devastating illnesses of our time. While many companies have tried to leverage the body’s own immune system to induce a powerful T cell response, most have been unsuccessful in inducing the right type and quantity of potent tumor-infiltrating T cells to execute a targeted attack. Scientists at PDS Biotech designed proprietary cationic, lipid-based nanoparticle platform technologies to overcome these limitations.
PDS Biotech is committed to developing novel immunotherapies based on our T cell activating platforms to save and improve the lives of patients worldwide:
- Versamune® based immunotherapies to provide a targeted T cell attack against tumor-associated proteins called antigens
- Versamune® based immunotherapy plus PDS0301, our novel tumor-targeting IL-12 immunotherapy, promotes enhanced infiltration and expansion of the T cells within the tumor to treat recurrent/metastatic cancers with poor survival prognosis
- Infectimune™ based vaccines to provide robust and durable protection against selected deadly infectious diseases
Product:
Versamune®
nanoparticle
platform technology
Versamune® is a novel investigational T cell activating platform which effectively stimulates a precise immune system response to a cancer-specific protein. Versamune® based immunotherapies promote a potent targeted T cell attack against cancers expressing the protein and are given by a simple subcutaneous injection and can be combined with standard of care treatments. Clinical data suggest Versamune® based immunotherapies demonstrate significant disease control by shrinking tumors, delaying disease progression and/or prolonging survival. Versamune® based immunotherapies have demonstrated minimal toxicity to date that may allow them to be safely combined with other treatments. Versamune® based investigational immunotherapies represent a transformative treatment approach for cancer patients and provide improved efficacy, safety and tolerability.
